These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
443 related articles for article (PubMed ID: 33501997)
1. Physiologically-Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID-19. Lutz JD; Mathias A; German P; Pikora C; Reddy S; Kirby BJ Clin Pharmacol Ther; 2021 Apr; 109(4):1116-1124. PubMed ID: 33501997 [TBL] [Abstract][Full Text] [Related]
2. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. Maharaj AR; Wu H; Hornik CP; Balevic SJ; Hornik CD; Smith PB; Gonzalez D; Zimmerman KO; Benjamin DK; Cohen-Wolkowiez M; JAMA Pediatr; 2020 Oct; 174(10):e202422. PubMed ID: 32501511 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Humeniuk R; Mathias A; Kirby BJ; Lutz JD; Cao H; Osinusi A; Babusis D; Porter D; Wei X; Ling J; Reddy YS; German P Clin Pharmacokinet; 2021 May; 60(5):569-583. PubMed ID: 33782830 [TBL] [Abstract][Full Text] [Related]
4. A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humans. Hanafin PO; Jermain B; Hickey AJ; Kabanov AV; Kashuba AD; Sheahan TP; Rao GG CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):89-99. PubMed ID: 33296558 [TBL] [Abstract][Full Text] [Related]
5. Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects. Humeniuk R; Mathias A; Cao H; Osinusi A; Shen G; Chng E; Ling J; Vu A; German P Clin Transl Sci; 2020 Sep; 13(5):896-906. PubMed ID: 32589775 [TBL] [Abstract][Full Text] [Related]
6. Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions. Deb S; Reeves AA J Pharm Pharm Sci; 2021; 24():277-291. PubMed ID: 34107241 [TBL] [Abstract][Full Text] [Related]
7. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit. Sun D AAPS J; 2020 May; 22(4):77. PubMed ID: 32458279 [TBL] [Abstract][Full Text] [Related]
8. Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2. Gallo JM Clin Transl Sci; 2021 May; 14(3):1082-1091. PubMed ID: 33404204 [TBL] [Abstract][Full Text] [Related]
14. Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review. Yang CJ; Wei YJ; Chang HL; Chang PY; Tsai CC; Chen YH; Hsueh PR J Microbiol Immunol Infect; 2021 Feb; 54(1):27-36. PubMed ID: 33060041 [TBL] [Abstract][Full Text] [Related]
15. Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature. Musa A; Pendi K; Hashemi A; Warbasse E; Kouyoumjian S; Yousif J; Blodget E; Stevens S; Aly B; Baron DA West J Emerg Med; 2020 May; 21(4):737-741. PubMed ID: 32726230 [TBL] [Abstract][Full Text] [Related]
16. Remdesivir as a broad-spectrum antiviral drug against COVID-19. Hong YN; Xu J; Sasa GBK; Zhou KX; Ding XF Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):541-548. PubMed ID: 33506946 [TBL] [Abstract][Full Text] [Related]
17. Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 Study. Ahmed A; Munoz FM; Muller WJ; Agwu A; Kimberlin DW; Galli L; Deville JG; Sue PK; Mendez-Echevarria A; Humeniuk R; Guo S; Rodriguez L; Han D; Hedskog C; Maxwell H; Palaparthy R; Kersey K; Rojo P; Pediatrics; 2024 Mar; 153(3):. PubMed ID: 38332740 [TBL] [Abstract][Full Text] [Related]
18. Compassionate Use of Remdesivir in Children With Severe COVID-19. Goldman DL; Aldrich ML; Hagmann SHF; Bamford A; Camacho-Gonzalez A; Lapadula G; Lee P; Bonfanti P; Carter CC; Zhao Y; Telep L; Pikora C; Naik S; Marshall N; Katsarolis I; Das M; DeZure A; Desai P; Cao H; Chokkalingam AP; Osinusi A; Brainard DM; Méndez-Echevarría A Pediatrics; 2021 May; 147(5):. PubMed ID: 33883243 [TBL] [Abstract][Full Text] [Related]
19. A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. Liang C; Tian L; Liu Y; Hui N; Qiao G; Li H; Shi Z; Tang Y; Zhang D; Xie X; Zhao X Eur J Med Chem; 2020 Sep; 201():112527. PubMed ID: 32563812 [TBL] [Abstract][Full Text] [Related]
20. Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance. Moirangthem DS; Surbala L Curr Drug Targets; 2021; 22(12):1346-1356. PubMed ID: 33267759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]